System: You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: The Company’s business in China has grown rapidly in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business has increased accordingly. Continued growth of the Company’s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company’s current in-line products, and the absence of trade impediments or adverse pricing controls. In recent years, the Chinese government has introduced and implemented a number of structural reforms to accelerate the shift to innovative products and reduce costs. Since 2017, there have been multiple new policies introduced by the government to improve access to new innovation, reduce the complexity of regulatory filings, and accelerate the review and approval process. This has led to a significant increase in the number of new products being approved each year. Additionally, in 2017, the Chinese government updated the National Reimbursement Drug List (NRDL) for the first time in eight years. While the mechanism for drugs being added to the list evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2020, drugs were added to the NRDL through double-digit price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through volume based Assistant:
- Assistant
Positive: The Company's operations in China have expanded swiftly over recent years, emphasizing China's growing significance to the Company's comprehensive pharmaceutical and vaccines business. Sustaining this expansion is reliant on fostering a conducive environment for innovative pharmaceutical products and vaccines, maintaining access to the Company's existing product line, and avoiding trade barriers or unfavorable pricing regulations. In recent times, the Chinese government has implemented several structural reforms aimed at facilitating a shift to innovative products and cutting costs. Since 2017, the government has rolled out numerous new policies to enhance access to novel innovations, simplify regulatory procedures, and hasten the review and approval process, leading to a notable rise in the annual number of approved new products. Furthermore, in 2017, the Chinese government revised the National Reimbursement Drug List (NRDL) for the first time in eight years. Although the process for listing drugs is changing, inclusion may necessitate price negotiations, potentially affecting the market outlook for certain brands. In 2020, drugs were included in the NRDL via substantial price cuts. Although pricing pressure has been a constant in China, health care reforms have intensified this pressure, partly due to the increased rate of generic substitution through volume-based methods.
Negative: The Company’s business in China has stagnated in recent years, reducing China's importance to the Company’s overall pharmaceutical and vaccines business. This stagnation is due to the lack of a favorable environment for innovative pharmaceutical products and vaccines, restricted access to the Company’s current in-line products, and imposition of trade impediments or adverse pricing controls. Contrary to recent claims, the Chinese government has not introduced any effective structural reforms to shift to innovative products and cut costs. Post-2017, there have been very few policies introduced to enhance access to new innovations or simplify regulatory processes, which has resulted in minimal increase in new product approvals each year. Additionally, the Chinese government has not updated the National Reimbursement Drug List (NRDL) effectively in years. The evolving drug listing mechanism now discourages inclusion due to challenging price negotiations, adversely affecting the market potential for certain brands. In 2020, the inclusion of drugs in the NRDL occurred without any notable benefit to pricing. Although there has been longstanding pricing pressure in China, health care reforms have not aggravated this pressure or promoted generic substitution.